| |
Innovative immune therapy advancements don't just happen anywhere. Discover why the industry's leaders choose Puerto Rico to impact the world. It's not what's next, it's where. 
|
|
Today’s Big NewsMar 27, 2024 |
| By Eric Sagonowsky Two months after closing its multibillion-dollar acquisition of Mirati Therapeutics, Bristol Myers Squibb is bidding adieu to more than 250 workers at the biotech's headquarters in California. |
|
|
|
By James Waldron Blackstone Life Sciences is making a $750 million bet on Moderna’s influenza vaccine program as part of the investment platform’s push to “support innovative mRNA technology.” |
By Conor Hale The agency previously took the rare step of banning the use these devices in March 2020, but the FDA's ban was overturned on appeal in July 2021. |
By Ben Adams It’s March, so it’s time for some #FierceMadness. Last year, we channeled the NCAA tournament for the best pharma ad campaigns, but this year we’re looking for the best of the best in drug names. |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! 
|
|
By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron What's the best biotech name? It's time to vote in the Fierce Madness #biotechbracket. |
By Max Bayer Moderna gave its clearest look yet at a third wave of vaccine products during the company's annual vaccines business review on Wednesday. Early-stage shots aimed at Epstein–Barr virus, norovirus and shingles could further solidify the biotech's infectious disease portfolio. |
By Angus Liu As geopolitical tensions threaten to disrupt pharmaceutical supply chains, AstraZeneca is making plans to manufacture drugs for the U.S. and China markets independently from one another. |
By Nick Paul Taylor Altimmune has been beaten by hepatitis B. The drug candidate, which Altimmune was preparing for partnering, failed to meet the bar for further development in a phase 2 study, prompting the biotech to stop development and focus on its GLP-1/glucagon dual receptor agonist. |
By Andrea Park Call it a silver lining: In addition to stopping the increasingly ludicrous theories for her absence from the public eye, Kate Middleton’s reveal last week that she’s fighting cancer may also be boosting awareness of the early signs and symptoms of the disease. |
By Nick Paul Taylor Drugmakers are bringing the fight for dominance of the diabetes and weight loss spaces to the airwaves, with MediaRadar finding six leading brands ramped up TV spending by 46% over the first two months of the year. |
By Conor Hale The main difference in the design of the Evolut FX+ is the addition of larger gaps that make it easier for a patient to undergo coronary procedures in the future. |
By Kevin Dunleavy Bayer is laying off 90 of its employees at its United States headquarters in Whippany, New Jersey, part of its ongoing restructure which CEO Bill Anderson has said will cost many their jobs. |
By Kevin Dunleavy After three years, the crown jewel of Merck’s $11.5 billion acquisition of Acceleron is ready to pay dividends. With the FDA’s approval of Winrevair (sotatercept) to treat pulmonary arterial hypertension (PAH), Merck is set to launch the first disease-modifying treatment for the condition. |
By Nick Paul Taylor Olympus has partnered with the American Lung Association (ALA) to get the word out about lung nodule diagnosis and staging, sponsoring educational resources that explain the process to patients. |
By Fraiser Kansteiner Despite headwinds, WuXi Biologics believes it is well positioned to capture new business opportunities in 2024. |
Fierce podcasts Don’t miss an episode |
| This week on “Podnosis,” we explore the pressing questions surrounding AI’s role in healthcare. From clinician trust to algorithm accuracy and patient privacy, there’s significant uncertainty about AI’s potential and impact in the healthcare sector, a topic that garnered considerable attention at this year’s South by Southwest conference. |
|
|---|
|
|
|
Thursday, April 11, 2024 | 11am ET / 8am PT As clinical trials increase in complexity, drug developers face growing pressure to deliver on-time, on-budget studies. FSP partnerships have emerged as a pivotal strategy to help address current challenges. Join us to learn moreas we explore the findings of The 2024 FSP Trends Report from the PPD clinical research business of Thermo Fisher Scientific. Sign up now! 
|
|
Whitepaper Explore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
